Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.

Medicilon and Binhui Biopharmaceutical have reached a strategic collaboration to jointly draw a new blueprint for the development of new biological drugs.webp

Gather and Work Together to Create Advantages
Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs

As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation for establishing deeper and broader collaborative relationships with global partners.

Binhui Bio has the only fully closed-loop industry-university-research integrated research platform in China for the development of oncolytic virus products - the oncolytic virus (oHSV2) immunotherapy platform. It collaborates with multiple technology platforms of nucleic acid drugs and protein drugs to develop new Class I biological drugs, and become a pioneer in the collaborative exploration of multi-platform technologies for tumor immunotherapy. The company's core oncolytic virus product BS001 (OH2 injection) has received NMPA and FDA approval for a total of 5 clinical approvals as a single drug and combination drug, becoming the first in the world to enter clinical research using type Ⅱ herpes simplex virus as a vector and obtain positive efficacy data of oncolytic viruses. It is also the first major national new drug creation project for oncolytic viruses to enter confirmatory phase III clinical research.

This powerful alliance between the two parties benefits from Medicilon's drug research and development service capabilities accumulated over the years, as well as Binhui Bio's successful experience in the field of new biological drug research and development. Based on the common vision and goals, both parties will give full play to their respective advantages in technology R&D and market expansion to achieve complementary advantages, effectively utilize resources, expand the market business scale of both parties, and create a professional contract R&D service platform. Both parties jointly promote the research, development and application of cutting-edge technologies such as oncolytic viruses, nucleic acid drugs and protein drugs.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客